Brind.

The FDA is currently reviewing concerns regarding mail-order abortion pills and the circulation of mifepristone.

Steady: 1 in the last 7 days Updated yesterday

The latest in this situation

  1. FDA takes regulatory action on mifepristone; Democrats control Senate committees.
  2. FDA relaxes mifepristone dispensing rules; DOJ refuses to enforce mail-in bans.

How it started

6 reports, 5 independent, last reported Wed 00:00. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 5 independent outlets

The FDA is currently reviewing concerns regarding mail-order abortion pills and the circulation of mifepristone.

Who's involved

What this event is mainly about
FDAUnited States of America

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA takes regulatory action on mifepristone; Democrats control Senate committees.1 source
  2. FDA relaxes mifepristone dispensing rules; DOJ refuses to enforce mail-in bans.1 source
  3. The FDA has approved the mail-order prescribing of abortion pills.1 source
  4. The FDA is facing scrutiny regarding mifepristone safety after study findings prompted the Trump administration to launch an investigation into drug safety.Sub-event
  5. FDA is reviewing mail-order abortion pills and concerns over mifepristone circulation.1 source
  6. FDA regulates mifepristone amid federal vs. state law conflict.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped